
    
      The proposal of the present study approved by our institutional review boards and
      institution's ethical committee, and all participants will sign a written consent before
      enter to study. All patients will be randomly divided into three groups and will be
      randomized to receive simvastatin 40 mg orally + vaginal placebo, simvastatin 40 mg vaginally
      + oral placebo and vaginal placebo + oral placebo for 3 months.

      CBC, Lipid profile, kidney & Liver function tests, FBS & hormonal evaluation will be
      performed before and after the treatment. Ultrasound examination will be performed before and
      after the treatment for determining of the number, size, and site of the myoma and also size
      of the uterus.
    
  